# OnCo record prostate-bcr (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/prostate-bcr/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "prostate-bcr" ;
  schema:name "Biochemical recurrence of prostate cancer"@en ;
  schema:alternateName "Biochemically recurrent prostate cancer"@en, "PSA recurrence"@en, "Rising PSA after local therapy"@en, "nmHSPC"@en, "Hormone-relapsed prostate cancer, PSA-only"@en, "Rising PSA after treatment"@en ;
  schema:description "Biochemical recurrence of prostate cancer is a rising PSA after surgery or radiotherapy with nothing yet visible on scans. Salvage radiotherapy can still cure it after surgery, and for a fast-doubling PSA the EMBARK trial showed that enzalutamide with or without hormone therapy delays spread."@en ;
  schema:url <https://onco.cc/cancers/prostate-bcr/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Biochemical_recurrence> ;
  schema:citation <https://en.wikipedia.org/wiki/Biochemical_recurrence>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459>, <https://www.nice.org.uk/guidance/ng131/chapter/Recommendations> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/prostate-high-risk/>, <https://onco.cc/cancers/prostate-intermediate-risk/>, <https://onco.cc/cancers/prostate-nmcrpc/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:terms <https://onco.cc/terms/psa-kinetics/>, <https://onco.cc/terms/cambridge-prognostic-group/>, <https://onco.cc/terms/extraprostatic-extension/>, <https://onco.cc/terms/tnm-prostate-cancer/>, <https://onco.cc/terms/psa-density/>, <https://onco.cc/terms/metastasis-free-survival/>, <https://onco.cc/terms/intermittent-androgen-deprivation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-embark-nejm-2023/>, <https://onco.cc/key-papers/paper-radicals-rt-lancet-2020/>, <https://onco.cc/key-papers/paper-propsma-hofman-lancet-2020/> ;
  onco:pipeline <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/ideas/idea-psma-pet-guided-mdt/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/terms/psa/>, <https://onco.cc/drugs/decipher-prostate/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/hifu-histotripsy/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/leuprolide/>, <https://onco.cc/trials/embark/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/terms/oligometastatic/>, <https://onco.cc/ideas/idea-psma-pet-guided-mdt/> .